RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cyclacel Pharmaceuticals Stock

Cyclacel Pharmaceuticals EBIT 2024

Cyclacel Pharmaceuticals EBIT

-16.04 M USD

Ticker

CYCC

ISIN

US23254L6039

WKN

A2P26W

In 2024, Cyclacel Pharmaceuticals's EBIT was -16.04 M USD, a -36.97% increase from the -25.45 M USD EBIT recorded in the previous year.

The Cyclacel Pharmaceuticals EBIT history

YEAREBIT (undefined USD)
2029e-
2028e143.94
2027e89.38
2026e-0.55
2025e-17.15
2024e-16.04
2023-25.45
2022-27.66
2021-22.94
2020-10.64
2019-9.68
2018-9.55
2017-9.49
2016-14.15
2015-16.17
2014-22.44
2013-17.97
2012-15.1
2011-15.75
2010-15.14
2009-17.93
2008-33.78
2007-31.48
2006-33.41
2005-20.78
2004-22.96

Cyclacel Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cyclacel Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cyclacel Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cyclacel Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cyclacel Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cyclacel Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cyclacel Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cyclacel Pharmaceuticals’s growth potential.

Cyclacel Pharmaceuticals Revenue, EBIT and net profit per share

DateCyclacel Pharmaceuticals RevenueCyclacel Pharmaceuticals EBITCyclacel Pharmaceuticals Net Income
2029e196.77 M undefined0 undefined22.14 M undefined
2028e163.11 M undefined143.94 M undefined23.73 M undefined
2027e111.29 M undefined89.38 M undefined15.59 M undefined
2026e102,000 undefined-553,860 undefined-3.19 M undefined
2025e51,000 undefined-17.15 M undefined-4 M undefined
2024e43,860 undefined-16.04 M undefined-6.29 M undefined
2023420,000 undefined-25.45 M undefined-22.76 M undefined
20220 undefined-27.66 M undefined-21.4 M undefined
20210 undefined-22.94 M undefined-19.09 M undefined
20200 undefined-10.64 M undefined-12.42 M undefined
20190 undefined-9.68 M undefined-8.03 M undefined
2018150,000 undefined-9.55 M undefined-7.49 M undefined
20170 undefined-9.49 M undefined-14.85 M undefined
2016840,000 undefined-14.15 M undefined-11.99 M undefined
20151.94 M undefined-16.17 M undefined-14.54 M undefined
20141.73 M undefined-22.44 M undefined-19.59 M undefined
20131.08 M undefined-17.97 M undefined-19.48 M undefined
201270,000 undefined-15.1 M undefined-13.91 M undefined
20110 undefined-15.75 M undefined-15.97 M undefined
2010110,000 undefined-15.14 M undefined-19.7 M undefined
2009910,000 undefined-17.93 M undefined-20.8 M undefined
2008880,000 undefined-33.78 M undefined-41.61 M undefined
2007130,000 undefined-31.48 M undefined-24.36 M undefined
2006390,000 undefined-33.41 M undefined-32.09 M undefined
2005360,000 undefined-20.78 M undefined-29.92 M undefined
2004930,000 undefined-22.96 M undefined-33.8 M undefined

Cyclacel Pharmaceuticals stock margins

The Cyclacel Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cyclacel Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cyclacel Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cyclacel Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Cyclacel Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cyclacel Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cyclacel Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cyclacel Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cyclacel Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cyclacel Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cyclacel Pharmaceuticals Margin History

Cyclacel Pharmaceuticals Gross marginCyclacel Pharmaceuticals Profit marginCyclacel Pharmaceuticals EBIT marginCyclacel Pharmaceuticals Profit margin
2029e40.66 %0 %11.25 %
2028e40.66 %88.25 %14.55 %
2027e40.66 %80.32 %14.01 %
2026e40.66 %-543 %-3,132.3 %
2025e40.66 %-33,634 %-7,840.6 %
2024e40.66 %-36,579.07 %-14,339.77 %
202340.66 %-6,060.24 %-5,418.1 %
202240.66 %0 %0 %
202140.66 %0 %0 %
202040.66 %0 %0 %
201940.66 %0 %0 %
201840.66 %-6,366.67 %-4,993.33 %
201740.66 %0 %0 %
201640.66 %-1,684.52 %-1,427.38 %
201540.66 %-833.51 %-749.48 %
201440.66 %-1,297.11 %-1,132.37 %
201340.66 %-1,663.89 %-1,803.7 %
201240.66 %-21,571.43 %-19,871.43 %
201140.66 %0 %0 %
201040.66 %-13,763.64 %-17,909.09 %
200940.66 %-1,970.33 %-2,285.71 %
200851.14 %-3,838.64 %-4,728.41 %
2007100 %-24,215.39 %-18,738.46 %
2006100 %-8,566.67 %-8,228.21 %
200540.66 %-5,772.22 %-8,311.11 %
200440.66 %-2,468.82 %-3,634.41 %

Cyclacel Pharmaceuticals Aktienanalyse

What does Cyclacel Pharmaceuticals do?

Cyclacel Pharmaceuticals Inc was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. The company was established by Dr. David Glover, an experienced biotechnology expert, and Dr. Paul Andrews, an oncology pioneer. Cyclacel Pharmaceuticals is a company specializing in the research and development of cancer drugs. It has two main divisions: clinical drug development and drug discovery. The company's business model is to develop innovative cancer drugs to meet the needs of patients with various types of cancer. The company utilizes an innovative approach by researching and developing cyclin-dependent kinase inhibitors (CDKIs) that aim to exploit the specific vulnerabilities of cancer cells. Cyclacel Pharmaceuticals currently offers four products: Seliciclib, Sapacitabin, CYC065, and CYC140. Seliciclib is a CDKI inhibitor that is currently in clinical development and being studied in a phase 2 trial for advanced cancer patients. Sapacitabin is a CDKI stabilizer that is currently being studied in a phase 3 trial for patients with acute myeloid leukemia (AML). CYC065 is a CDKI inhibitor that is still in preclinical development and currently being tested in drug discovery. CYC140 is another CDKI target that is in preclinical development and aims to eliminate cancer cells. Cyclacel Pharmaceuticals has achieved many significant milestones in its history, including the FDA approval of Seliciclib and Sapacitabin as orphan drugs for the treatment of AML. The company has also formed important partnerships with other pharmaceutical companies to further develop and distribute its drug class. Overall, Cyclacel Pharmaceuticals pursues a promising strategy in the fight against cancer through the research and development of CDKI regulators. Although the company has only a few products on the market, it is well positioned to continue growing and developing innovative drugs that can improve patients' lives. Cyclacel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Cyclacel Pharmaceuticals's EBIT

Cyclacel Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Cyclacel Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Cyclacel Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Cyclacel Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Cyclacel Pharmaceuticals stock

How much did Cyclacel Pharmaceuticals achieve in EBIT for the current year?

In the current year, Cyclacel Pharmaceuticals has achieved an EBIT of -16.04 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Cyclacel Pharmaceuticals.

How has the EBIT of Cyclacel Pharmaceuticals developed in recent years?

The EBIT of Cyclacel Pharmaceuticals has increased by -36.968% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Cyclacel Pharmaceuticals?

The EBIT of Cyclacel Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Cyclacel Pharmaceuticals pay?

Over the past 12 months, Cyclacel Pharmaceuticals paid a dividend of 0.15 USD . This corresponds to a dividend yield of about 14.56 %. For the coming 12 months, Cyclacel Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cyclacel Pharmaceuticals?

The current dividend yield of Cyclacel Pharmaceuticals is 14.56 %.

When does Cyclacel Pharmaceuticals pay dividends?

Cyclacel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cyclacel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cyclacel Pharmaceuticals located?

Cyclacel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cyclacel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cyclacel Pharmaceuticals from 8/1/2016 amounting to 0.15 USD, you needed to have the stock in your portfolio before the ex-date on 7/13/2016.

When did Cyclacel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/1/2016.

What was the dividend of Cyclacel Pharmaceuticals in the year 2023?

In the year 2023, Cyclacel Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cyclacel Pharmaceuticals pay out the dividend?

The dividends of Cyclacel Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Cyclacel Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Cyclacel Pharmaceuticals

Our stock analysis for Cyclacel Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyclacel Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.